close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Medical History

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Medical History

Review your patient’s information.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Beth Hellerstedt

location-icon

Round Rock, TX

LOCATION OF PRACTICE
St. David's Round Rock Medical Center
MEDICAL Specialty:

Bone Cancer, Breast Cancer, Metastatic Respiratory System Cancer



2410 ROUND ROCK AVE STE 150, ROUND ROCK, TX, 786814019
PO BOX 911230, DALLAS, TX, 753911230
512-341-8724
NPI Number
1215975487
ABOUT

Beth Hellerstedt, MD, is a Medical Oncologist in Austin, TX. She frequently treats conditions like Breast Cancer, Metastatic Respiratory System Cancer, and Bone Cancer. She graduated from the University of Pennsylvania Perelman School of Medicine and completed her residency at the University of Michigan Health System.

Dr. Beth Hellerstedt profile image

Published Articles

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.- 2019 Mar
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.- 2018 Jun
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.- 2016 May 10
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.- 2014 Dec 1
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.- 2013 Jun
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.- 2012 Jul
Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.- 2012 Mar
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.- 2011 Feb 2
Postsplenectomy cytomegalovirus mononucleosis is a distinct clinicopathologic syndrome.- 2010 Apr
Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.- 2008 May-Jun

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider